Delivery Order SPE2DR25D9114-SPE2DR26FMDY2
- Not listed
- The Defense Logistics Agency awarded a $77,830.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on October 20, 2025, with an ultimate completion date of November 10, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,301.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 17, 2025, with an ultimate completion date of December 9, 2025, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal...
- The Defense Logistics Agency awarded a $79,430.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Perjeta 420 mg/14 mL vials. The award, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation and was issued without subcontractor involvement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency awarded a $41,441.33 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The award was issued on November 13, 2025, with an ultimate completion date of December 5, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery...
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. on August 19, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, will be performed at the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a woman-owned small business pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $13,671.78 by the Defense Logistics Agency on August 6, 2025, with an ultimate completion date of August 27, 2025. The delivery order covers Perjeta 420 mg/14 mL vials, an oncology treatment medication, with no set-aside designation applied. This award was issued under DMS Pharmaceutical Group's existing single-award...
- SPE2DR25D9114Indefinite Delivery Contract
- SPE2DR25D9114-SPE2DR26FMDY2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $27,905.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supporting the Department of Defense's pharmaceutical supply needs. DMS Pharmaceutical Group has been registered in the System for Award Management since 2001 and serves as a critical supplier within the federal pharmaceutical supply chain, delivering an extensive portfolio of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare facilities worldwide. The parent IDC contract, designated SPE2DR and awarded November 13, 2025, carries a $500 million ceiling value with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. This delivery order for Perjeta, an oncology treatment, exemplifies DMS Pharmaceutical Group's role in fulfilling the specialized and diverse pharmaceutical requirements of Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 11/18/25 |